Adalimumab has been studied in several clinical trials for the following conditions:
Adalimumab for Ankylosing Spondylitis
Clinical studies have shown that adalimumab is effective at improving the symptoms of
ankylosing spondylitis, including
back pain and morning stiffness. People taking adalimumab showed greater improvements in their symptoms of ankylosing spondylitis, compared to those not taking adalimumab.
Adalimumab for Crohn's Disease
Adalimumab was also studied for treating
Crohn's disease. In one study, up to 58 percent of those taking adalimumab showed significant improvement in their
Crohn's disease symptoms, compared to just 34 percent of those not taking adalimumab. Adalimumab also increased the chance of remission and helped keep the
symptoms of Crohn's disease from returning.
Adalimumab for Juvenile Idiopathic Arthritis
In studies, children with juvenile idiopathic
arthritis who were given adalimumab with or without methotrexate (Rheumatrex
®, another medication) were less likely to have a disease flare, compared to children who were not given adalimumab.
Adalimumab for Plaque Psoriasis
In one study, up to 71 percent of people who were treated with adalimumab for 16 weeks for
plaque psoriasis had "clear" or "minimal" disease, compared to just 10 percent of people who were not given adalimumab.
Adalimumab for Psoriatic Arthritis
In a study of adalimumab for
psoriatic arthritis, adalimumab was shown to reduce pain and other
psoriatic arthritis symptoms, including joint stiffness. Also, adalimumab helped to lessen the physical joint changes of psoriatic arthritis, compared to those not taking adalimumab.
Previous
Add this article to your Favorites
Email this article
Print